OCT4: A novel biomarker for dysgerminoma of the ovary

Liang Cheng, Antoinette Thomas, Lawrence M. Roth, Wenxin Zheng, Helen Michael, Fadi W Abdul Karim

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

The prognosis and therapy for dysgerminomas are different from those of other ovarian tumor types, making accurate diagnosis imperative for patient care. OCT4 (POU5F1) is a transcription factor involved in the regulation of pluripotency during embryonic development. It can be detected in both pluripotent cells and other early germ cells. This study examines the expression of OCT4 in both dysgerminoma and nondysgerminomatous neoplasms involving the ovary. Formalin-fixed, paraffin-embedded cell blocks of 33 cases of dysgerminoma including 2 cases of gonadoblastoma associated with dysgerminoma and 3 cases of metastatic dysgerminoma, and 111 cases of nondysgerminomatous neoplasms involving the ovary were stained using the antibody against OCT4. All cases of dysgerminomas and gonadoblastomas were positive for OCT4 with strong nuclear staining. More than 90% of dysgerminoma cells in each case showed diffuse strong nuclear staining. In addition, 3 metastatic dysgerminomas also showed uniform strong nuclear staining. All nondysgerminomatous tumors (mature teratoma, 14; yolk sac tumor, 4; Sertoli-Leydig cell tumor, 15; granulosa cell tumor, 22; Brenner tumor, 3; carcinoid tumor, 4; struma ovarii, 2; fibroma, 5; thecoma, 1; serous adenocarcinoma, 5; endometrioid adenocarcinoma, 4; small cell carcinoma, 6; stromal sarcoma, 1; malignant lymphoma, 6; metastatic malignant melanoma, 1; metastatic carcinoid, 2; metastatic small cell carcinoma, 1; and metastatic lobular carcinoma of the breast, 1) were negative for OCT4, except for some cases of clear cell adenocarcinoma of the ovary. Four of 14 clear cell adenocarcinomas showed focal positive nuclear immunoreactivity for OCT4. OCT4 is a sensitive and relatively specific biomarker for the detection of dysgerminoma. It may also be useful in the diagnosis of gonadoblastoma, which contains similar cells and may be associated with dysgerminoma. OCT4 may aid in the detection of small foci of metastatic dygerminoma in extraovarian sites and may also help distinguish dysgerminoma from other primary and metastatic tumors of the ovary.

Original languageEnglish
Pages (from-to)1341-1346
Number of pages6
JournalAmerican Journal of Surgical Pathology
Volume28
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

Dysgerminoma
Ovary
Biomarkers
Gonadoblastoma
Clear Cell Adenocarcinoma
Small Cell Carcinoma
Carcinoid Tumor
Staining and Labeling
Ovarian Neoplasms
Struma Ovarii
Brenner Tumor
Thecoma
Sertoli-Leydig Cell Tumor
Granulosa Cell Tumor
Endodermal Sinus Tumor
Endometrioid Carcinoma
Lobular Carcinoma
Neoplasms
Fibroma
Teratoma

Keywords

  • Adolescent
  • Biomarker
  • Differential diagnosis
  • Dysgerminoma
  • Germ cell tumors
  • Gonadoblastoma
  • Histogenesis
  • Neoplasia
  • OCT3/4
  • Ovary
  • POU5F1

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

OCT4 : A novel biomarker for dysgerminoma of the ovary. / Cheng, Liang; Thomas, Antoinette; Roth, Lawrence M.; Zheng, Wenxin; Michael, Helen; Karim, Fadi W Abdul.

In: American Journal of Surgical Pathology, Vol. 28, No. 10, 10.2004, p. 1341-1346.

Research output: Contribution to journalArticle

Cheng, Liang ; Thomas, Antoinette ; Roth, Lawrence M. ; Zheng, Wenxin ; Michael, Helen ; Karim, Fadi W Abdul. / OCT4 : A novel biomarker for dysgerminoma of the ovary. In: American Journal of Surgical Pathology. 2004 ; Vol. 28, No. 10. pp. 1341-1346.
@article{09f6492e4e974d62b5da19441e7662d8,
title = "OCT4: A novel biomarker for dysgerminoma of the ovary",
abstract = "The prognosis and therapy for dysgerminomas are different from those of other ovarian tumor types, making accurate diagnosis imperative for patient care. OCT4 (POU5F1) is a transcription factor involved in the regulation of pluripotency during embryonic development. It can be detected in both pluripotent cells and other early germ cells. This study examines the expression of OCT4 in both dysgerminoma and nondysgerminomatous neoplasms involving the ovary. Formalin-fixed, paraffin-embedded cell blocks of 33 cases of dysgerminoma including 2 cases of gonadoblastoma associated with dysgerminoma and 3 cases of metastatic dysgerminoma, and 111 cases of nondysgerminomatous neoplasms involving the ovary were stained using the antibody against OCT4. All cases of dysgerminomas and gonadoblastomas were positive for OCT4 with strong nuclear staining. More than 90{\%} of dysgerminoma cells in each case showed diffuse strong nuclear staining. In addition, 3 metastatic dysgerminomas also showed uniform strong nuclear staining. All nondysgerminomatous tumors (mature teratoma, 14; yolk sac tumor, 4; Sertoli-Leydig cell tumor, 15; granulosa cell tumor, 22; Brenner tumor, 3; carcinoid tumor, 4; struma ovarii, 2; fibroma, 5; thecoma, 1; serous adenocarcinoma, 5; endometrioid adenocarcinoma, 4; small cell carcinoma, 6; stromal sarcoma, 1; malignant lymphoma, 6; metastatic malignant melanoma, 1; metastatic carcinoid, 2; metastatic small cell carcinoma, 1; and metastatic lobular carcinoma of the breast, 1) were negative for OCT4, except for some cases of clear cell adenocarcinoma of the ovary. Four of 14 clear cell adenocarcinomas showed focal positive nuclear immunoreactivity for OCT4. OCT4 is a sensitive and relatively specific biomarker for the detection of dysgerminoma. It may also be useful in the diagnosis of gonadoblastoma, which contains similar cells and may be associated with dysgerminoma. OCT4 may aid in the detection of small foci of metastatic dygerminoma in extraovarian sites and may also help distinguish dysgerminoma from other primary and metastatic tumors of the ovary.",
keywords = "Adolescent, Biomarker, Differential diagnosis, Dysgerminoma, Germ cell tumors, Gonadoblastoma, Histogenesis, Neoplasia, OCT3/4, Ovary, POU5F1",
author = "Liang Cheng and Antoinette Thomas and Roth, {Lawrence M.} and Wenxin Zheng and Helen Michael and Karim, {Fadi W Abdul}",
year = "2004",
month = "10",
doi = "10.1097/01.pas.0000135528.03942.1f",
language = "English",
volume = "28",
pages = "1341--1346",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - OCT4

T2 - A novel biomarker for dysgerminoma of the ovary

AU - Cheng, Liang

AU - Thomas, Antoinette

AU - Roth, Lawrence M.

AU - Zheng, Wenxin

AU - Michael, Helen

AU - Karim, Fadi W Abdul

PY - 2004/10

Y1 - 2004/10

N2 - The prognosis and therapy for dysgerminomas are different from those of other ovarian tumor types, making accurate diagnosis imperative for patient care. OCT4 (POU5F1) is a transcription factor involved in the regulation of pluripotency during embryonic development. It can be detected in both pluripotent cells and other early germ cells. This study examines the expression of OCT4 in both dysgerminoma and nondysgerminomatous neoplasms involving the ovary. Formalin-fixed, paraffin-embedded cell blocks of 33 cases of dysgerminoma including 2 cases of gonadoblastoma associated with dysgerminoma and 3 cases of metastatic dysgerminoma, and 111 cases of nondysgerminomatous neoplasms involving the ovary were stained using the antibody against OCT4. All cases of dysgerminomas and gonadoblastomas were positive for OCT4 with strong nuclear staining. More than 90% of dysgerminoma cells in each case showed diffuse strong nuclear staining. In addition, 3 metastatic dysgerminomas also showed uniform strong nuclear staining. All nondysgerminomatous tumors (mature teratoma, 14; yolk sac tumor, 4; Sertoli-Leydig cell tumor, 15; granulosa cell tumor, 22; Brenner tumor, 3; carcinoid tumor, 4; struma ovarii, 2; fibroma, 5; thecoma, 1; serous adenocarcinoma, 5; endometrioid adenocarcinoma, 4; small cell carcinoma, 6; stromal sarcoma, 1; malignant lymphoma, 6; metastatic malignant melanoma, 1; metastatic carcinoid, 2; metastatic small cell carcinoma, 1; and metastatic lobular carcinoma of the breast, 1) were negative for OCT4, except for some cases of clear cell adenocarcinoma of the ovary. Four of 14 clear cell adenocarcinomas showed focal positive nuclear immunoreactivity for OCT4. OCT4 is a sensitive and relatively specific biomarker for the detection of dysgerminoma. It may also be useful in the diagnosis of gonadoblastoma, which contains similar cells and may be associated with dysgerminoma. OCT4 may aid in the detection of small foci of metastatic dygerminoma in extraovarian sites and may also help distinguish dysgerminoma from other primary and metastatic tumors of the ovary.

AB - The prognosis and therapy for dysgerminomas are different from those of other ovarian tumor types, making accurate diagnosis imperative for patient care. OCT4 (POU5F1) is a transcription factor involved in the regulation of pluripotency during embryonic development. It can be detected in both pluripotent cells and other early germ cells. This study examines the expression of OCT4 in both dysgerminoma and nondysgerminomatous neoplasms involving the ovary. Formalin-fixed, paraffin-embedded cell blocks of 33 cases of dysgerminoma including 2 cases of gonadoblastoma associated with dysgerminoma and 3 cases of metastatic dysgerminoma, and 111 cases of nondysgerminomatous neoplasms involving the ovary were stained using the antibody against OCT4. All cases of dysgerminomas and gonadoblastomas were positive for OCT4 with strong nuclear staining. More than 90% of dysgerminoma cells in each case showed diffuse strong nuclear staining. In addition, 3 metastatic dysgerminomas also showed uniform strong nuclear staining. All nondysgerminomatous tumors (mature teratoma, 14; yolk sac tumor, 4; Sertoli-Leydig cell tumor, 15; granulosa cell tumor, 22; Brenner tumor, 3; carcinoid tumor, 4; struma ovarii, 2; fibroma, 5; thecoma, 1; serous adenocarcinoma, 5; endometrioid adenocarcinoma, 4; small cell carcinoma, 6; stromal sarcoma, 1; malignant lymphoma, 6; metastatic malignant melanoma, 1; metastatic carcinoid, 2; metastatic small cell carcinoma, 1; and metastatic lobular carcinoma of the breast, 1) were negative for OCT4, except for some cases of clear cell adenocarcinoma of the ovary. Four of 14 clear cell adenocarcinomas showed focal positive nuclear immunoreactivity for OCT4. OCT4 is a sensitive and relatively specific biomarker for the detection of dysgerminoma. It may also be useful in the diagnosis of gonadoblastoma, which contains similar cells and may be associated with dysgerminoma. OCT4 may aid in the detection of small foci of metastatic dygerminoma in extraovarian sites and may also help distinguish dysgerminoma from other primary and metastatic tumors of the ovary.

KW - Adolescent

KW - Biomarker

KW - Differential diagnosis

KW - Dysgerminoma

KW - Germ cell tumors

KW - Gonadoblastoma

KW - Histogenesis

KW - Neoplasia

KW - OCT3/4

KW - Ovary

KW - POU5F1

UR - http://www.scopus.com/inward/record.url?scp=5044233906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5044233906&partnerID=8YFLogxK

U2 - 10.1097/01.pas.0000135528.03942.1f

DO - 10.1097/01.pas.0000135528.03942.1f

M3 - Article

C2 - 15371950

AN - SCOPUS:5044233906

VL - 28

SP - 1341

EP - 1346

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 10

ER -